Current Status and Prospects of Viral Vector-Based Gene Therapy to Treat Kidney Diseases
Human Gene Therapy · 01.03.2024 · 35 (5-6) · 139-150
DOI: 10.1089/hum.2023.184 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Gene Therapy, erschienen am 01.03.2024. Verfasst von Louise Medaer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, Faculty of Medicine. Hauptthemen laut MEDLINE: Quality of Life, Kidney Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 92 Literaturangaben.
Abstract (Originalsprache)
Inherited kidney diseases are among the leading causes of chronic kidney disease, reducing the quality of life and resulting in substantial socioeconomic impact. The advent of early genetic testing and the growing understanding of the molecular basis and pathophysiology of these disorders have opened avenues for novel treatment strategies. Viral vector-based gene therapies have evolved from experimental treatments for rare diseases to potent platforms that carry the intrinsic potential to provide a cure with a single application. Several gene therapy products have reached the market, and the numbers are only expected to increase. Still, none target inherited kidney diseases. Gene transfer to the kidney has lagged when compared to other tissue-directed therapies such as hepatic, neuromuscular, and ocular tissues. Systemic delivery of genetic information to tackle kidney disease is challenging. The pharma industry is taking steps to take on kidney disease and to translate the current research into the therapeutic arena. In this review, we provide an overview of the current viral vector-based approaches and their potential. We discuss advances in platforms and injection routes that have been explored to enhance gene delivery toward kidney cells in animal models, and how these can fuel the development of viable gene therapy products for humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, Faculty of Medicine.
- Laboratory of Paediatric Nephrology, Department of Development and Regeneration, Faculty of Medicine.
- Leuven Viral Vector Core, Faculty of Medicine; KU Leuven, Leuven, Belgium.
ORCID-Profile: Louise Medaer, Koenraad Veys, Rik Gijsbers
Zitieren
APA
Medaer, L., Veys, K., & Gijsbers, R. (2024). Current Status and Prospects of Viral Vector-Based Gene Therapy to Treat Kidney Diseases. Human Gene Therapy, 35(5-6), 139-150. https://doi.org/10.1089/hum.2023.184
Vancouver
Medaer L, Veys K, Gijsbers R. Current Status and Prospects of Viral Vector-Based Gene Therapy to Treat Kidney Diseases. Human Gene Therapy. 2024;35(5-6):139-150. doi:10.1089/hum.2023.184
BibTeX
@article{Medaer2024,
author = {Medaer, Louise and Veys, Koenraad and Gijsbers, Rik},
title = {Current Status and Prospects of Viral Vector-Based Gene Therapy to Treat Kidney Diseases},
journal = {Human Gene Therapy},
year = {2024},
volume = {35},
number = {5-6},
pages = {139--150},
doi = {10.1089/hum.2023.184}
}
EUVIMED